TBPH
Price:
$9.49
Market Cap:
$474.51M
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise...[Read more]
Industry
Biotechnology
IPO Date
2014-05-16
Stock Exchange
NASDAQ
Ticker
TBPH
According to Theravance Biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -8.04. This represents a change of 8.26% compared to the average of -7.43 of the last 4 quarters.
The mean historical PE Ratio of Theravance Biopharma, Inc. over the last ten years is -6.43. The current -8.04 PE Ratio has changed 12.40% with respect to the historical average. Over the past ten years (40 quarters), TBPH's PE Ratio was at its highest in in the September 2022 quarter at 0.21. The PE Ratio was at its lowest in in the June 2022 quarter at -21.09.
Average
-6.43
Median
-6.25
Minimum
-11.26
Maximum
-3.07
Discovering the peaks and valleys of Theravance Biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 143.38%
Maximum Annual PE Ratio = -3.07
Minimum Annual Increase = -34.55%
Minimum Annual PE Ratio = -11.26
Year | PE Ratio | Change |
---|---|---|
2024 | -8.15 | -27.66% |
2023 | -11.26 | 26.61% |
2022 | -8.90 | 131.12% |
2021 | -3.85 | -3.42% |
2020 | -3.98 | -34.55% |
2019 | -6.09 | -4.98% |
2018 | -6.41 | 25.26% |
2017 | -5.12 | -31.57% |
2016 | -7.48 | 143.38% |
2015 | -3.07 | 53.68% |
The current PE Ratio of Theravance Biopharma, Inc. (TBPH) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-9.43
5-year avg
-7.23
10-year avg
-6.43
Theravance Biopharma, Inc.’s PE Ratio is less than Neoleukin Therapeutics, Inc. (-0.67), less than Instil Bio, Inc. (-2.06), less than Achilles Therapeutics plc (-0.89), less than NextCure, Inc. (-0.28), less than Assembly Biosciences, Inc. (-2.55), less than Nuvation Bio Inc. (-1.26), less than CytomX Therapeutics, Inc. (4.46), less than Sensei Biotherapeutics, Inc. (-0.26), less than Graphite Bio, Inc. (-3.84), greater than Merrimack Pharmaceuticals, Inc. (-8.92), less than Ovid Therapeutics Inc. (-1.44), less than Connect Biopharma Holdings Limited (-2.92),
Company | PE Ratio | Market cap |
---|---|---|
-0.67 | $8.20M | |
-2.06 | $161.44M | |
-0.89 | $60.83M | |
-0.28 | $13.94M | |
-2.55 | $103.57M | |
-1.26 | $763.34M | |
4.46 | $335.57M | |
-0.26 | $7.55M | |
-3.84 | $185.19M | |
-8.92 | $223.97M | |
-1.44 | $20.39M | |
-2.92 | $45.61M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Theravance Biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Theravance Biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Theravance Biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for Theravance Biopharma, Inc. (TBPH)?
What is the highest PE Ratio for Theravance Biopharma, Inc. (TBPH)?
What is the 3-year average PE Ratio for Theravance Biopharma, Inc. (TBPH)?
What is the 5-year average PE Ratio for Theravance Biopharma, Inc. (TBPH)?
How does the current PE Ratio for Theravance Biopharma, Inc. (TBPH) compare to its historical average?